News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,065 Results
Type
Article (46345)
Company Profile (335)
Press Release (665385)
Section
Business (209040)
Career Advice (2180)
Deals (35985)
Drug Delivery (108)
Drug Development (82197)
Employer Resources (187)
FDA (16292)
Job Trends (15208)
News (352184)
Policy (33169)
Tag
Academia (2719)
Alliances (50818)
Alzheimer's disease (1330)
Approvals (16251)
Artificial intelligence (176)
Bankruptcy (359)
Best Places to Work (11792)
Biotechnology (228)
Breast cancer (207)
Cancer (1553)
Cardiovascular disease (125)
Career advice (1824)
CAR-T (116)
Cell therapy (329)
Clinical research (65661)
Collaboration (587)
Compensation (309)
COVID-19 (2629)
C-suite (138)
Data (1481)
Diabetes (191)
Diagnostics (6353)
Earnings (85885)
Employer resources (161)
Events (113851)
Executive appointments (495)
FDA (17076)
Funding (529)
Gene therapy (229)
GLP-1 (669)
Government (4490)
Healthcare (19118)
Infectious disease (2729)
Inflammatory bowel disease (119)
Interviews (342)
IPO (16602)
Job creations (3837)
Job search strategy (1566)
Layoffs (445)
Legal (8029)
Lung cancer (232)
Manufacturing (224)
Medical device (13386)
Medtech (13391)
Mergers & acquisitions (19647)
Metabolic disorders (516)
Neuroscience (1707)
NextGen: Class of 2025 (6710)
Non-profit (4642)
Northern California (1885)
Obesity (299)
Opinion (204)
Patents (136)
People (58627)
Phase I (20439)
Phase II (28902)
Phase III (21540)
Pipeline (617)
Postmarket research (2641)
Preclinical (8879)
Radiopharmaceuticals (245)
Rare diseases (292)
Real estate (6213)
Regulatory (22231)
Research institute (2467)
Resumes & cover letters (374)
Southern California (1628)
Startups (3768)
United States (16939)
Vaccines (605)
Weight loss (213)
Date
Today (138)
Last 7 days (401)
Last 30 days (1990)
Last 365 days (35571)
2025 (1770)
2024 (35986)
2023 (40861)
2022 (51924)
2021 (56499)
2020 (54902)
2019 (47649)
2018 (35937)
2017 (33085)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (789)
Arizona (212)
Asia (39078)
Australia (6419)
California (4298)
Canada (1558)
China (368)
Colorado (197)
Connecticut (207)
Europe (84704)
Florida (606)
Georgia (155)
Illinois (430)
Indiana (249)
Maryland (699)
Massachusetts (3334)
Michigan (198)
Minnesota (333)
New Jersey (1202)
New York (1219)
North Carolina (822)
Northern California (1885)
Ohio (155)
Pennsylvania (1008)
South America (1168)
Southern California (1628)
Texas (629)
Utah (122)
Washington State (433)
712,065 Results for "cassava sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Cassava Sciences Provides a Business Update - January 7, 2025
January 8, 2025
·
8 min read
Press Releases
Cassava Sciences to Hold Corporate Update on November 25th
November 25, 2024
·
1 min read
Press Releases
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
November 18, 2024
·
5 min read
Alzheimer’s disease
Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as Company Hit With New Lawsuit
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase IIb performance of its Alzheimer’s disease drug candidate.
September 27, 2024
·
2 min read
·
Tristan Manalac
Lone Star Bio
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
Cassava Sciences, Inc., a biotechnology company focused on Alzheimer’s disease, announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders.
May 8, 2024
·
5 min read
Press Releases
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
November 26, 2024
·
8 min read
Press Releases
Cassava Sciences Reports Q3 2024 Financial and Operating Results
November 8, 2024
·
11 min read
Drug Development
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
Cassava Sciences, Inc., a biotechnology company focused on Alzheimer’s disease, reported financial results for first quarter ended March 31, 2024.
May 10, 2024
·
11 min read
1 of 71,207
Next
